A5089499530- Renal cell carcinoma treatment
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Renal and related cancers
- Estrogen and related hormone effects
- Pancreatic and Hepatic Oncology Research
- Chronic Lymphocytic Leukemia Research
- Bladder and Urothelial Cancer Treatments
- Ferroptosis and cancer prognosis
- Colorectal Cancer Treatments and Studies
- Advanced Breast Cancer Therapies
- Immune Cell Function and Interaction
- Sarcoma Diagnosis and Treatment
- HER2/EGFR in Cancer Research
- Lung Cancer Treatments and Mutations
- Economic and Financial Impacts of Cancer
- Viral-associated cancers and disorders
- Immunotherapy and Immune Responses
- Lung Cancer Research Studies
- T-cell and B-cell Immunology
- COVID-19 Clinical Research Studies
- Cancer-related Molecular Pathways
- Single-cell and spatial transcriptomics
Dana-Farber Cancer Institute
2016-2025
Research Network (United States)
2023-2024
Harvard University
2018-2024
Human Longevity (United States)
2024
University of California, San Diego
2024
ECOG-ACRIN Cancer Research Group
2018-2022
Forestry Research Institute of Nigeria
2019-2021
University of North Texas Health Science Center
2016-2021
Morehouse School of Medicine
2021
University of North Texas
2016-2021
To validate currently used recurrence prediction models for renal cell carcinoma (RCC) by using prospective data from the ASSURE (ECOG-ACRIN E2805; Adjuvant Sorafenib or Sunitinib Unfavorable Renal Carcinoma) adjuvant trial.Eight RCC (University of California at Los Angeles Integrated Staging System [UISS]; Stage, Size, Grade, and Necrosis [SSIGN]; Leibovich; Kattan; Memorial Sloan Kettering Cancer Center [MSKCC]; Yaycioglu; Karakiewicz; Cindolo) were selected on basis their use in clinical...
Abstract Purpose: Immune-related RECIST (irRECIST) were designed to capture atypical responses seen with immunotherapy. We hypothesized that, in patients metastatic clear cell renal carcinoma (mccRCC), candidate biomarkers for nivolumab response would show improved association clinical endpoints capturing responders compared standard (RECISTv1.1). Experimental Design: Endpoints based on RECISTv1.1 [objective rate (ORR)/progression-free survival (PFS)] or irRECIST [immune-related ORR...
Blockade of the PD1 pathway is a broadly effective cancer therapy, but additional immune-inhibitory pathways contribute to tumor immune evasion. HERV-H LTR-associating 2 (HHLA2; also known as B7H5 and B7H7) member B7 family immunoregulatory ligands that mediates costimulatory effects through its interaction with CD28 transmembrane immunoglobulin domain containing (TMIGD2). However, HHLA2 has been have inhibitory on T cells. Here, we report identified killer cell immunoglobulin-like receptor,...
To determine the value of tumor cell programmed death-ligand 1 (PD-L1) expression as a predictive biomarker nivolumab monotherapy efficacy in treatment-naive patients with clear renal carcinoma (ccRCC) and salvage nivolumab/ipilimumab tumors unresponsive to monotherapy.
Abstract Immune checkpoint inhibitors (ICI) targeting the PD-1 pathway have transformed treatment of advanced renal cell carcinoma (RCC), but mechanisms underlying therapeutic response remain largely unknown. Herein, we perform transcriptomic analysis on RCC biospecimens from 102 patients enrolled in a phase II clinical trial frontline nivolumab (NCT03117309) to investigate determinants anti-PD1 monotherapy. Through bulk analysis, identify an enrichment genes associated with tertiary...
Abstract Purpose: We sought to validate levels of CD8+ tumor-infiltrating cells (TIC) expressing PD-1 but not TIM-3 and LAG-3 (IF biomarker; Pignon colleagues, 2019) investigate human endogenous retroviruses (hERV) as predictors response anti–PD-1 in a randomized trial nivolumab (nivo) versus everolimus (evero) patients with metastatic clear cell renal carcinoma (mccRCC; CheckMate-025). Experimental Design: Tumor tissues (nivo: n = 116, evero: 107) were analyzed by multiparametric...
Abstract Background In metastatic urothelial carcinoma (mUC), predictive biomarkers that correlate with response to immune checkpoint inhibitors (ICIs) are lacking. Here, we interrogated genomic and clinical features associated ICIs in mUC. Methods Sixty two mUC patients treated ICI who had targeted tumour sequencing were studied. We examined associations between candidate benefit (CB, any objective reduction size) versus no (NCB, change or increase size). Both univariable multivariable...
5006 Background: Nivolumab (nivo) is FDA approved for pts with VEGFR TKI-resistant RCC and the nivo + ipilimumab (nivo/ipi) combination treatment naïve IMDC intermediate poor risk RCC. Little information available on efficacy toxicity of monotherapy in or nivo/ipi salvage therapy tumors resistant to initial monotherapy. Methods: Eligible received 240mg IV q2 wk x 6 doses followed by 360mg q3 4 480 mg q4 until progressive disease (PD), toxicity, completion 96 wks (Part A). Pts PD prior stable...
Background To determine the efficacy and toxicity of nivolumab monotherapy in treatment-naïve patients with non-clear cell renal carcinoma (nccRCC) nivolumab/ipilimumab salvage therapy tumors unresponsive to initial monotherapy. Methods Eligible nccRCC received until progressive disease (PD), toxicity, or completion 96 weeks treatment (Part A). Patients PD prior to, stable (SD) at 48 (prolonged SD) were potentially eligible receive B). required submit tissue from a metastatic lesion obtained...
JCO
Abstract Purpose: Programmed cell death protein 1 (PD-1) expression on CD8+TIM-3−LAG-3− tumor-infiltrating cells predicts positive response to PD-1 blockade in metastatic clear-cell renal carcinoma (mccRCC). Because inhibition of signaling regulatory T (Treg) augments their immunosuppressive function, we hypothesized that Tregs would predict resistance inhibitors. Experimental Design: PD-1+ were phenotyped using multiparametric immunofluorescence ccRCC tissues from the CheckMate-025 trial...
101 Background: MATCH is a trial that assigns patients (pts) with solid tumors, lymphomas, or multiple myeloma to specific targeted therapies based on genetic alterations identified in fresh tumor biopsies. Arm I evaluated the PI3-kinase inhibitor taselisib pts activating mutations PIK3CA, catalytic subunit of PI3-kinase. Methods: Pts KRAS PTEN mutation loss were excluded, as breast squamous lung cancer. received 4 mg po daily 28 d cycles until progression intolerable toxicity. Staging was...
Background As part of a partitioned survival analysis, treatment-free (TFS) can characterize the overall time patients spend between cessation immunotherapy and start subsequent therapy; both with without toxicity. Significant TFS was reported for nivolumab/ipilimumab arms CheckMate 067 214 trials advanced melanoma or renal cell carcinoma (aRCC), respectively, where often halted toxicity rather than predefined treatment endpoint. We therefore sought to assess in HCRN GU16-260 trial, which...
Follicular lymphoma (FL) exhibits considerable variability in biological features and clinical trajectories across patients. To dissect the diversity of FL, we utilized a Bernoulli mixture model to identify genetic subtypes 713 pre-treatment tumor tissue samples. Our analysis revealed existence five with unique profiles that correlated clinicopathological characteristics. The clusters were enriched specific mutations as follows: CS (CREBBP STAT6), TT (TNFAIP3 TP53), GM (GNA13 MEF2B), Q...
<p>Supplementary Figure 1: Progression Free and Overall Survival in the Eligible Treated Population (n=38) Kaplan Meier plots for progression free (A) overall (B) survival eligible treated population (n=38)</p>
<div>AbstractPurpose:<p>Amplification of cyclin-dependent kinase 4 (CDK4) and CDK6 is a feature variety malignancies, preclinical evidence suggests that inhibition CDK4/6 plausible treatment strategy in these tumors. Subprotocol Z1C the NCI-Molecular Analysis for Therapy Choice trial was designed to evaluate inhibitor palbociclib CDK4- or CDK6-amplified tumors.</p>Patients Methods:<p>Patients had solid malignancy lymphoma with progression on at least one systemic...
598 Background: PD-1 directed immune checkpoint inhibitors are effective in many tumor types, including kidney cancers. HHLA2 is a negative checkpoint, generally expressed on PD-L1 clear cell renal carcinomas (ccRCC) (Bhatt, et al. 2021). Therapeutics targeting either or its inhibitory receptor KIR3DL3 Phase I trials and predictive biomarkers needed to help direct treatment. We previously reported that efficacy of nivolumab correlated with status patients cancer treated the first line...
590 Background: Inhibition of PD-1 signaling in regulatory T cells (Tregs) has been shown to enhance their immunosuppressive function. We previously demonstrated that high levels expression on tumor-infiltrating Tregs are associated with resistance nivolumab (nivo) monotherapy pretreated patients advanced clear cell renal carcinoma (ccRCC) from the CheckMate-025 trial (Denize et al, 2024). Here, we aim validate these findings first-line setting. Methods: Primary tumor tissues ccRCC (n=70)...
591 Background: TLS are organized lymphoid aggregates linked to improved response immunotherapy in multiple cancers, including mRCC. Traditionally, assessment relies on pathological staining of tumor sections. In this study, we evaluated the performance gene-expression signatures as an alternative diagnostic tool. Methods: Primary tumors from treatment-naïve patients with mRCC HCRN GU16-260 trial were analyzed using multiparametric immunofluorescence (IF), for CD3, CD20 (TLS), CD21 (mature...